CME Background Information

To obtain credit, study the material and complete the CME Posttest and Registration Form as instructed at the end of each activity.

Objective

After completing these educational activities, you should be able to:

• formulate a treatment plan based on the latest evidence-based treatment options for patients with bipolar disorder

Statement of Need and Purpose

Bipolar disorder remains challenging to diagnose and treat. Even among patients who receive the correct diagnosis, many receive inadequate treatment. Increased awareness of new pharmacotherapies and the role of psychosocial management of bipolar disorder is imperative to improve its treatment. These activities were designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc. who have requested information on the treatment of bipolar disorder. There are no prerequisites for participating in these activities.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc. designates each of these educational activities for up to 0.25 Category 1 credit toward the AMA Physician’s Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity.

Date of Original Release/Review

These Brief Reports were published in June and July 2005 and are eligible for CME credit through July 31, 2007. The latest review of this material was June 2005.

Faculty Disclosure

In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest, (i.e., a proprietary entity producing health care goods or services) occurring within the 12 months prior to joining this activity. The CME Institute has resolved any conflicts of interest that were identified. The disclosures are as follows:

• Dr. Bowden [see disclosure]
• Dr. Ketter [see disclosure]
• Dr. Sachs [see disclosure]
• Dr. Thase [see disclosure]

Disclosure of Off-Label Usage

In these Brief Reports, investigational information about pharmaceutical agents may be presented that is outside U.S. Food and Drug Administration-approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. Please consult the paragraph titled "Disclosure of Off-Label Usage" at the end of each Brief Report for a complete listing of off-label or investigational uses. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Review Process

These activities have undergone a 3-tier review process: (1) the entire faculty discussed the content at a peer-review planning session; (2) the Chair reviewed each activity for accuracy and fair balance; and (3) a member of the External CME Advisory Board reviewed the activities to determine whether the material is evidence-based and objective.

Acknowledgment

These Brief Reports are developed from the teleconference "The Journal of Clinical Psychiatry Current Reports: Focus on Bipolar Disorder Treatment," which was held May 2, 2005, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc. pursuant to an educational grant from GlaxoSmithKline. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.